Novo Nordisk Withholding Tresiba From German HTA Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.